Autoimmunity in Retinitis Pigmentosa | NCT00433277 | Trialant
Unknown statusInterventionalNot ApplicableUpdated Feb 9, 2007
Autoimmunity in Retinitis Pigmentosa
ClinicalTrials.gov ID
NCT00433277
Lead Sponsor
Semmelweis UniversityOTHER
Overall Status
Unknown status
Study Type
Interventional
Phase
Not Applicable
Last Update Posted
Feb 9, 2007Estimated
Brief Summary
Using local immune suppression, the trial seeks evidence for the hypothesis that autoimmunity plays a role in the pathomechanism of retinitis pigmentosa.
Retinitis Pigmentosa
twice-daily dosage with 0.5% cyclosporine-A eyedrops
Ages Eligible for Study
Child (0-17)Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No data available
Eligibility Criteria
Inclusion Criteria:
Clinical diagnosis of retinitis pigmentosa
Exclusion Criteria:
Cataract
Extremely low ERG wave amplitude (less than 8% of normal)